Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study

PURPOSE: To characterize the pharmacokinetics (PK) of, and perform an exploratory exposure–response (E–R) analysis for, pertuzumab in patients with HER2-positive early breast cancer (EBC) within the APHINITY study (NCT01358877, BIG 4–11/BO25126/TOC4939G). METHODS: A previously developed pertuzumab t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirschbrown, Whitney P., Kågedal, Matts, Wang, Bei, Lindbom, Lars, Knott, Adam, Mack, Rachelle, Monemi, Sharareh, Nijem, Ihsan, Girish, Sandhya, Freeman, Christie, Fumagalli, Debora, McConnell, Robin, Jerusalem, Guy, Twelves, Chris, Baselga, José, von Minckwitz, Gunter, Bines, José, Garg, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499763/
https://www.ncbi.nlm.nih.gov/pubmed/30976844
http://dx.doi.org/10.1007/s00280-019-03826-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499763/
https://www.ncbi.nlm.nih.gov/pubmed/30976844
http://dx.doi.org/10.1007/s00280-019-03826-1

Ejemplares similares